All In Biotech

Drug Trial Radar · NCT07791303

Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Centre Study of Single and Repeated Dosing of Ascending Doses, to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Ketamir-2 in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

57

Actual

Start

Mar 20, 2025

Primary completion

Mar 5, 2026

Study completion Mar 5, 2026

Sponsor

Lead sponsor
MIRA PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Aug 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of oral Ketamir-2 in healthy adult participants. The study includes single ascending dose cohorts and multiple ascending dose cohorts.

Conditions

  • Healthy Adult Participants

Interventions

  • Ketamir-2Drug

    Ketamir-2, also referred to as Ketamir hemipamoate, was administered orally as capsules containing 50 mg or 300 mg. Participants randomized to active treatment received Ketamir-2 according to assigned dose cohort. Cohorts 1 through 4 received a single dose on Day 1. Cohorts 5 through 7 received once-daily dosing from Day 1 through Day 5. Capsules were swallowed together with a glass of water after an overnight fast.

  • PlaceboDrug

    Placebo capsules were identical in appearance to active capsules and were administered orally according to the same number of capsules and dosing schedule as the corresponding Ketamir-2 dose cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Incidence of adverse eventsTime frame: From first dose through dosing period until 7 days post last dose
  2. Number of Participants With Clinically Significant Clinical Laboratory AbnormalitiesTime frame: From baseline through end of study visit
  3. Number of Participants With Clinically Significant Vital Sign AbnormalitiesTime frame: From baseline through end of study visit
  4. Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities on a 12-Lead ECGTime frame: From baseline through end of study visit
  5. Number of Participants With Clinically Significant Physical Examination FindingsTime frame: From baseline through end of study visit
  6. Number of Participants With Ketamine-Related Side Effects as Assessed by the Ketamine Side Effect Tool (KSET)Time frame: From baseline through end of study visit
  7. Change From Baseline in Bowdle Visual Analog Scale (VAS) ScoreTime frame: From baseline through end of study visit

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hadassah Clinical Research Unit

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.